Literature DB >> 12473768

Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients.

Y K Nakao1, M Motomura, T Fukudome, T Fukuda, H Shiraishi, T Yoshimura, M Tsujihata, K Eguchi.   

Abstract

The authors characterized the clinical and immunologic features of 110 patients with Lambert-Eaton myasthenic syndrome (LEMS). Anti-P/Q-type voltage-gated calcium channels (VGCC) antibodies were detected in 85% of the patients (seropositive) but not in the rest (seronegative). Except for the indication that small cell lung carcinoma is less common in seronegative patients, no significant differences were found in the clinical characteristics of patients who had or did not have anti-P/Q-type VGCC antibodies. The results of passive transfer experiments suggest that seronegative LEMS is also an autoantibody-mediated disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473768     DOI: 10.1212/01.wnl.0000037485.56217.5f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Lambert-Eaton Myasthenic syndrome associated with sarcoidosis.

Authors:  F Purroy García; M Comabella; N Raguer; J Majó; X Montalban
Journal:  J Neurol       Date:  2005-04-20       Impact factor: 4.849

Review 2.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

3.  Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.

Authors:  Rodica Di Lorenzo; Karin Mente; Jianbo Li; Luay Shayya; Alexander Rae-Grant; Yuebing Li; Adham Jammoul
Journal:  J Neurol       Date:  2018-07-09       Impact factor: 4.849

Review 4.  Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

Authors:  A Evoli; R Liguori; A Romani; R Mantegazza; A Di Muzio; B Giometto; E Pegoraro; C Rodolico; M C Vigliani
Journal:  Neurol Sci       Date:  2014-01-31       Impact factor: 3.307

Review 5.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

Review 6.  Neurologic paraneoplastic syndromes.

Authors:  Edward J Dropcho
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 7.  Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.

Authors:  Tyler B Tarr; Peter Wipf; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

Review 8.  The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.

Authors:  Sarah Ew Briggs; Paul Gozzard; Denis C Talbot
Journal:  Immunotargets Ther       Date:  2013-05-21

Review 9.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

10.  Lung adenocarcinoma with Lambert-Eaton myasthenic syndrome indicated by voltage-gated calcium channel: a case report.

Authors:  Hiromasa Arai; Kenji Inui; Kazuki Hashimoto; Kazuki Kan-O; Teppei Nishii; Hitaru Kishida; Koji Okudela; Masahiro Tsuboi; Akinori Nozawa; Takeshi Kaneko; Munetaka Masuda
Journal:  J Med Case Rep       Date:  2012-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.